The Turkish Journal of Ear Nose and Throat
Yazarlar: Candan Demiroz Abakay, Kadriye Şahintürk, Ali Türk, Lütfi Özkan, Afşin Özmen
Konular:-
DOI:10.5606/kbbihtisas.2014.00344
Anahtar Kelimeler:Radiation therapy,Salivary gland tumor,Survival.
Özet: OBJECTIVE: This study aims to evaluate our single center experience in patients with a salivary gland tumor receiving postoperative radiation therapy (RT). METHODS: Between January 1996 and December 2011, the records of 34 salivary gland tumor patients who were operated and referred to our clinic for adjuvant RT were retrospectively analyzed. Radiation therapy was applied to the primary tumor and lymphatics at a median dose of 60 Gy (54 to 60 Gy) with 1.8-2 Gy/fraction. RESULTS: The median follow-up was 38 months (range, 3 to 204 months). The most common site of involvement was the parotid gland in 21 patients (62%), followed by the submandibulary gland in 11 patients (%24) and minor salivary gland in two patients (9%). Five-year overall survival (OS) was 49% (range, 3 to 206 months) and disease free survival (DFS) was 61% (range, 1 to 173 months). Six patients had local or regional recurrences (18%), while 13 patients (38%) had distant metastasis. A tumor size larger than 4 cm, over six weeks referral time to RT, and existence of metastatic lymph node were found to be poor prognostic factors for OS (p=0.023, p=0.039, respectively), and DFS (p=0.046). While extracapsulary involvement significantly reduced the DFS and OS (p=0.022, p=0.050, respectively), overall RT time affected DFS alone (p=0.046). CONCLUSION: We recommend adjuvant RT in high-risk patients operated due to a salivary gland tumor.